ToxSci Advance Access published online on November 3, 2004
Toxicological Sciences, doi:10.1093/toxsci/kfi022
Toxicological Sciences © Society of Toxicology 2004; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
* To whom correspondence should be addressed. Troglitazone (TRO), an effective thiazolidinedione antidiabetic agent, was reported to produce idiosyncratic hepatotoxic effects in some individuals. In contrast, rosiglitazone (RSG), in the same group of agents, has no significant toxic effects and now is widely used. In this study, human hepatoma (HepG2) cell lines were exposed to various doses of TRO as well as RSG (0, 25, 50 and 75 µM) for 48 h. Cell lysates were separated by 2-dimensional electrophoresis and the gels were stained with coomassie brilliant blue to compare the spot profiles. The greatest protein expression at a MW of 75 kDa and isoelectric point of 5 was specifically increased with TRO treatments of 50 and 75 µM. The spot was identified as a mixture of immunoglobulin heavy chain binding protein (BiP) and, to a lesser extent, protein disulfide isomerase related protein (PDIrp). Immunoblot analyses showed that the BiP protein was dose-dependently increased by TRO treatment and, to a lower degree, by RSG. These effects were also correlated with the high induction of BiP mRNA by TRO (50 and 75 µM) and the lower induction by RSG. However, both treatments showed no significant effects on PDIrp expression. The toxic effects of TRO in relation to the overexpression of BiP were also demonstrated in HLE cells, another human hepatoma cell line. In HLE cells, the inhibition of BiP expression by small interference RNA rendered cells more susceptible to the toxic effects of TRO. These results suggest that the overexpression of BiP was a defense mechanism of the endoplasmic reticulum in response to TRO-induced toxicity.
Accepted October 25, 2004
In Vitro Toxicology
Chaperone Proteins Involved in Troglitazone-Induced Toxicity in Human Hepatoma Cell Lines
Tsuyoshi Yokoi, E-mail: TYOKOI{at}kenroku.kanazawa-u.ac.jp
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Schardt, D. Weber, M. Eyholzer, B. U. Mueller, and T. Pabst Activation of the Unfolded Protein Response Is Associated with Favorable Prognosis in Acute Myeloid Leukemia Clin. Cancer Res., June 1, 2009; 15(11): 3834 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anwar-Mohamed and A. O. S. El-Kadi Down-Regulation of the Carcinogen-Metabolizing Enzyme Cytochrome P450 1a1 by Vanadium Drug Metab. Dispos., September 1, 2008; 36(9): 1819 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Das, W. S. Chu, A. K. Mondal, N. K. Sharma, P. A. Kern, N. Rasouli, and S. C. Elbein Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E393 - E400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Chambers, S. M. Weber, and J. A. Corbett PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1052 - E1061. [Abstract] [Full Text] [PDF]
|
|